Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.41 |
| ▸ | STS | P08842 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | SOD1 | P00441 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215719 | 1.00 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL2215975 | 0.92 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL3847372 | 0.91 | SMN1; SMN2 (0.37) | CA2STSESR1RORC | |
| SCHEMBL3847345 | 0.88 | RORC (0.33) | CA2ESR1RORC | |
| SCHEMBL2213456 | 0.88 | CA2 (0.35) | CA2STSESR1SOD1CA1 | |
| SCHEMBL5172821 | 0.84 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL2214509 | 0.84 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL5149829 | 0.84 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL3845724 | 0.84 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL3847363 | 0.83 | SMN1; SMN2 (0.36) | CA2STSESR1CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039702-A2 | Prodrugs erbeta-selective substances, method for their production and pharmaceutical compounds containing these compositions | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | CYP19A1, ESR2, HSD17B11 | CA2 326/4885STS 229/4885ESR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.